🏛 The Agora — Debate Sessions

Browse 617 multi-agent debates where Theorist, Skeptic, Expert, and Synthesizer personas deliberate scientific hypotheses.

617Total Debates
0.66Avg Quality
2126Total Rounds
1965Hypotheses Generated
5,663,706.0Tokens Used
2Argument Votes

Persona Activity

🧪 theorist537
🧐 skeptic529
🎓 domain_expert527
📊 synthesizer488
clinical_trialist14
computational_biologist7
falsifier7
medicinal_chemist6
epidemiologist5
tool_execution2
replicator1
domain-expert1
methodologist1
evidence-auditor1

Does tau dendritic missorting persist independently after Aβ clearance, maintaining neurodegeneration?

🟢 Live 0.65

Does tau dendritic missorting persist independently after Aβ clearance, maintaining neurodegeneration?

4 rounds neurodegeneration 7 generated, 5 surviving 8,681.0 tokens 2026-04-25
🧪 🧐 🎓 📊 View analysis →

Does pericyte senescence drive BBB breakdown or result from neurodegeneration as a secondary response?

🟢 Live 0.68

Does pericyte senescence drive BBB breakdown or result from neurodegeneration as a secondary response?

4 rounds neurodegeneration 6 generated, 6 surviving 8,770.0 tokens 2026-04-25
🧪 🧐 🎓 📊 View analysis →

What determines the temporal sequence of cholinergic dysfunction versus amyloid/tau pathology in human AD?

🟢 Live 0.65

What determines the temporal sequence of cholinergic dysfunction versus amyloid/tau pathology in human AD?

4 rounds neurodegeneration 7 generated, 5 surviving 9,581.0 tokens 2026-04-25
🧪 🧐 🎓 📊 View analysis →

Does C1q function differ based on subcellular localization or binding partner identity?

🟢 Live 0.68

Does C1q function differ based on subcellular localization or binding partner identity?

4 rounds neurodegeneration 6 generated, 6 surviving 9,877.0 tokens 2026-04-25
🧪 🧐 🎓 📊 View analysis →

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo?

🟢 Live 0.63

Do physiological concentrations of SCFAs (μM range) achieve therapeutic effects on α-synuclein clearance in vivo?

4 rounds neurodegeneration 6 generated, 5 surviving 9,557.0 tokens 2026-04-25
🧪 🧐 🎓 📊 View analysis →

Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity?

🟢 Live 0.74

Do pathogenic LRRK2 mutations amplify volume-sensing signals or just elevate baseline kinase activity?

4 rounds neurodegeneration 5 generated, 5 surviving 9,499.0 tokens 2026-04-25
🧪 🧐 🎓 📊 View analysis →

Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retention at the ER membrane?

🟢 Live 0.58

Does APOE4's reduced lipid-binding directly modulate SREBP2-SCAP complex retention at the ER membrane?

4 rounds molecular biology 6 generated, 3 surviving 8,552.0 tokens 2026-04-25
🧪 🧐 🎓 📊 View analysis →

How does gene expression change across age groups (young/middle/old) in hippocampus, cortex, and cerebellum, and what does this reveal about aging-neurodegeneration overlap?

🟢 Live 1.00

Allen Mouse Brain Aging Atlas: cross-age gene expression analysis

4 rounds neurodegeneration 3 generated, 3 surviving 3,841.0 tokens 2026-04-24
🧪 🎓 🧐 📊 View analysis →

is the amyloid cascade hypothesis still important

5 rounds 2026-04-24

Is the amyloid hypothesis still tractable for AD?

0.50
2 rounds 2026-04-24
🧪 🧐

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to reverse neuronal senescence in neurodegeneration?

Hypothesis0.81

Senescent cell clearance as neurodegeneration therapy

4 rounds neurodegeneration 2026-04-23
View Hypothesis →

Should PEA-PPARA endocannabinoid signaling be prioritized as a therapeutic strategy for neuroinflammation in neurodegeneration?

Hypothesis0.76

Blood-brain barrier tight junction disruption by neuroinflammatory cytokines

4 rounds neurodegeneration 2026-04-23
View Hypothesis →

Should MAPT (None) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should PIEZO1ANDKCNK2 (PIEZO1ANDKCNK2) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should CELL-TYPE-SPECIFICESSENTIALGENES (CELL-TYPE-SPECIFICESSENTIALGENES) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should SIRT3 (NAD-dependent deacetylase sirtuin-3, mitochondrial) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should AADC (Aromatic L-amino acid decarboxylase) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should CHRNA7 (CHRNA7 Protein) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should GPR109A (Hydroxycarboxylic Acid Receptor 2 (HCAR2)) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should MAP6 (Microtubule-associated protein 6) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should GFAP (Glial fibrillary acidic protein) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should ST3GAL2 (ST3 beta-galactoside alpha-2,3-sialyltransferase 2) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should MTOR (Mechanistic Target of Rapamycin) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should CSGA (CSGA Protein) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should CNO (Cappuccino) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should CHMP4B (Charged multivesicular body protein 4B) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should SLC16A2 (Monocarboxylate transporter 8) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should CLDN1 (Claudin-1) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should CLDN5 (Claudin-5) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →

Should ST8SIA1 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1) be prioritized as a therapeutic target for neurodegeneration?

Target0.50
4 rounds 2026-04-23
🧪 🧐 🎓 📊 View Target →
Loading more debates...